KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Assets (2016 - 2025)

Biomarin Pharmaceutical's Current Assets history spans 17 years, with the latest figure at $4.0 billion for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 22.31% year-over-year to $4.0 billion, compared with a TTM value of $4.0 billion through Dec 2025, up 22.31%, and an annual FY2025 reading of $4.0 billion, up 22.31% over the prior year.
  • Current Assets for Q4 2025 was $4.0 billion at Biomarin Pharmaceutical, up from $3.9 billion in the prior quarter.
  • The five-year high for Current Assets was $4.0 billion in Q4 2025, with the low at $2.3 billion in Q4 2021.
  • Average Current Assets over 5 years is $2.9 billion, with a median of $3.0 billion recorded in 2023.
  • Year-over-year, Current Assets fell 15.6% in 2021 and then rose 26.11% in 2025.
  • Tracing BMRN's Current Assets over 5 years: stood at $2.3 billion in 2021, then grew by 20.98% to $2.8 billion in 2022, then rose by 7.44% to $3.0 billion in 2023, then grew by 9.35% to $3.2 billion in 2024, then increased by 22.31% to $4.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Current Assets are $4.0 billion (Q4 2025), $3.9 billion (Q3 2025), and $3.8 billion (Q2 2025).